[HTML][HTML] Inflammatory pathways of importance for management of inflammatory bowel disease
J Pedersen, M Coskun, C Soendergaard… - World journal of …, 2014 - ncbi.nlm.nih.gov
Inflammatory bowel disease (IBD) is a group of chronic disorders of the gastrointestinal tract
comprising Crohn's disease (CD) and ulcerative colitis (UC). Their etiologies are unknown …
comprising Crohn's disease (CD) and ulcerative colitis (UC). Their etiologies are unknown …
TNF-alpha blockers in inflammatory bowel diseases: practical recommendations and a user's guide: an update
M Vulliemoz, S Brand, P Juillerat, C Mottet… - Digestion, 2020 - karger.com
Background: Anti-tumour necrosis factor-alpha (anti-TNF) antagonists have been the
mainstay in the treatment of inflammatory bowel diseases (IBDs) for over 20 years …
mainstay in the treatment of inflammatory bowel diseases (IBDs) for over 20 years …
[HTML][HTML] Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy
Rationale: Anti-tumor necrosis factor (TNF) therapy is a very effective way to treat
inflammatory bowel disease. However, systemic exposure to anti-TNF-α antibodies through …
inflammatory bowel disease. However, systemic exposure to anti-TNF-α antibodies through …
Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases
CM Olesen, M Coskun, L Peyrin-Biroulet… - Pharmacology & …, 2016 - Elsevier
Biological treatment with tumor necrosis factor (TNF) inhibitors is successful in the
management of inflammatory bowel disease (IBD). All TNF inhibitors antagonize the pro …
management of inflammatory bowel disease (IBD). All TNF inhibitors antagonize the pro …
Decoy exosomes as a novel biologic reagent to antagonize inflammation
N Duong, K Curley, A Brown, A Campanelli… - International Journal …, 2019 - Taylor & Francis
Background: Exosomes are ubiquitous naturally secreted stable nanovesicles that can be
engineered to target and deliver novel therapeutics to treat a host of human diseases …
engineered to target and deliver novel therapeutics to treat a host of human diseases …
Oroxyloside prevents dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB pathway through PPARγ activation
X Wang, Y Sun, Y Zhao, Y Ding, X Zhang… - Biochemical …, 2016 - Elsevier
Oroxyloside, as a metabolite of oroxylin A, may harbor various beneficial bioactivities which
have rarely been reported in the previous studies. Here we established the dextran sulfate …
have rarely been reported in the previous studies. Here we established the dextran sulfate …
[HTML][HTML] New strategies for treatment of inflammatory bowel disease
OH Nielsen - Frontiers in medicine, 2014 - frontiersin.org
The etiology of inflammatory bowel disease (IBD), of which ulcerative colitis (UC) and
Crohn's disease (CD) are the two most prevailing entities, is unknown. However, IBD is …
Crohn's disease (CD) are the two most prevailing entities, is unknown. However, IBD is …
[HTML][HTML] GL-V9, a new synthetic flavonoid derivative, ameliorates DSS-induced colitis against oxidative stress by up-regulating Trx-1 expression via activation of AMPK …
Y Zhao, Y Sun, Y Ding, X Wang, Y Zhou, W Li… - Oncotarget, 2015 - ncbi.nlm.nih.gov
GL-V9, a new synthesized flavonoid derivative, has been reported to possess anti-cancer
properties in our previous studies. Uncontrolled overproduction of reactive oxygen species …
properties in our previous studies. Uncontrolled overproduction of reactive oxygen species …
Ectoines as novel anti-inflammatory and tissue protective lead compounds with special focus on inflammatory bowel disease and lung inflammation
L Bethlehem, G van Echten-Deckert - Pharmacological Research, 2021 - Elsevier
The compatible solute ectoine is one of the most abundant and powerful cytoprotectant in
the microbial world. Due to its unique ability to stabilize biological membranes and …
the microbial world. Due to its unique ability to stabilize biological membranes and …
Redeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel disease
Tumor necrosis factor (TNF) and its receptors TNFR1 and TNFR2 are major therapeutic
targets for inflammatory bowel disease. Research advances have demonstrated that TNF …
targets for inflammatory bowel disease. Research advances have demonstrated that TNF …